Shenzhen OK Biotech Technology Co., Ltd. (SZOB)
Categories

     Shenzhen OK Biotech Technology Co., Ltd.(SZOB)

     HK Add: 6/F, Fo Tan Industrial Centre, 26-28 Au Pui Wan St ,Fo Tan, Shatin, Hongkong

     China mainland Add: 8F, Fuxuan Building, No. 46, East Heping Rd, Longhua New  District,  Shenzhen, PRC China

     Email: nicole@ok-biotech.com

        smile@ok-biotech.com

     Web: www.ok-biotech.com

     Tel: +852 6679 4580

You are here: Home > News > Content

Anastrozole, CAS 120511-73-1 Wishes To Help The Younger Australian Women With Breast Cancer

Edit: Shenzhen OK Biotech Technology Co., Ltd. (SZOB)    Date: Oct 27, 2015

Anastrozole, CAS 120511-73-1 wishes to help the Younger Australian women with breast cancer

Study shows at least one young women dies every week from the disease, and five-year survival rate for those aged 20-29 is worse than for over 40s

The Field of Women event to raise awareness about breast cancer before last year’s AFL match between Melbourne and the Western Bulldogs. 

Australian women in their 20s and 30s with breast cancer are more likely to die from the disease than older women.


The Australian Institute of Health and Welfare Breast Cancer in Young Women report, released on Monday, shows more than two breast cancers are diagnosed every day among women aged 20 to 39, and at least one young woman dies every week from the disease.


Young women are expected to account for 5% of new breast cancer cases in Australia in 2015, and 2.1% of breast cancer deaths. This year, an estimated 795 young women will be diagnosed, and 65 will die.


Breast cancer is still relatively rare among young women, but the report shows those diagnosed have a lower survival rate than women over 40.


The five-year relative survival rate for women aged 20 to 29 is 86%, compared with 90% for women over 40.


Institute spokesman Justin Harvey said there tended to be a higher proportion of very large breast cancers in young women than older women, associated with a lower survival rate.


But even with small breast cancers, women aged 20 to 39 had a survival rate of 93%, compared with 99% for older women.


The reason for the poorer survival rate is unclear, the report says, but is likely to be related to differences in cancer characteristics, such as larger cancers and higher grades.


All survivors often face emotional, physical and financial challenges as a result of their illness, the report says, but in the long term young women tend to be more at risk of physical and psychosocial distress.


“These young women are at a life stage in which they are building careers, establishing relationships and planning for a family,” Cancer Australia chief executive Professor Helen Zorbas said.


The report says young victims of the disease feel “too young” to have cancer, have higher levels of fear that the cancer could return than older women and are afraid of loss of fertility and early menopause as a result of treatment.


The financial implications are also greater, because they are more likely to be at the start or middle of their careers, and may find it difficult to re-enter the workforce after treatment.


Related tags: Anastrozole - Prescription drug, side effects anastrozole, anastrozole arimidex, arimidex, anastrozole men, letrozole, anastrozole breast cancer, anastrozole dosage, buy arimidex, arimidex buy,

Product Categories
Contact Us
Address: HK: 6/F,Fo Tan Industrial Centre,26-28 Au Pui Wan St,Fo Tan,Shatin,Hongkong Shenzhen: 8F, Fuxuan Building, No. 46, East Heping Rd, Longhua New District, Shenzhen, PRC China
Tel: +852 6679 4580
 Fax:
 E-mail:smile@ok-biotech.com
Shenzhen OK Biotech Technology Co., Ltd.(SZOB)
Share: